Key Square Capital Management LLC Buys New Stake in HUTCHISON CHINA/S (NASDAQ:HCM)

Share on StockTwits

Key Square Capital Management LLC bought a new position in HUTCHISON CHINA/S (NASDAQ:HCM) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,102,872 shares of the company’s stock, valued at approximately $24,263,000. HUTCHISON CHINA/S accounts for about 8.8% of Key Square Capital Management LLC’s portfolio, making the stock its 5th biggest position. Key Square Capital Management LLC owned about 0.83% of HUTCHISON CHINA/S at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in HCM. Aperio Group LLC acquired a new stake in shares of HUTCHISON CHINA/S in the second quarter worth $50,000. Quantamental Technologies LLC raised its position in shares of HUTCHISON CHINA/S by 607.9% during the second quarter. Quantamental Technologies LLC now owns 2,782 shares of the company’s stock valued at $61,000 after buying an additional 2,389 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of HUTCHISON CHINA/S in the second quarter valued at about $91,000. FACTORIAL MANAGEMENT Ltd bought a new stake in shares of HUTCHISON CHINA/S in the second quarter valued at about $205,000. Finally, Rathbone Brothers plc acquired a new stake in HUTCHISON CHINA/S during the second quarter worth about $208,000. Hedge funds and other institutional investors own 29.65% of the company’s stock.

NASDAQ HCM traded up $0.11 during trading on Wednesday, reaching $21.83. 5,234 shares of the company traded hands, compared to its average volume of 215,029. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.19 and a current ratio of 4.33. The stock’s 50 day moving average price is $20.72 and its two-hundred day moving average price is $25.62. The company has a market cap of $2.89 billion, a price-to-earnings ratio of -38.21 and a beta of 0.67. HUTCHISON CHINA/S has a 1-year low of $19.20 and a 1-year high of $39.68.

Several brokerages recently issued reports on HCM. ValuEngine upgraded HUTCHISON CHINA/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded HUTCHISON CHINA/S from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research note on Wednesday, July 10th. BidaskClub raised HUTCHISON CHINA/S from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 3rd. Finally, Macquarie started coverage on shares of HUTCHISON CHINA/S in a research note on Friday, July 5th. They set an “outperform” rating on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $25.41.

About HUTCHISON CHINA/S

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.

See Also: How Does the Quiet Period Work?

Want to see what other hedge funds are holding HCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HUTCHISON CHINA/S (NASDAQ:HCM).

Institutional Ownership by Quarter for HUTCHISON CHINA/S (NASDAQ:HCM)

Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Encompass Health  Research Coverage Started at Deutsche Bank
Encompass Health Research Coverage Started at Deutsche Bank
Critical Contrast: PlusTherapeuticsInc   .  vs. Stryker
Critical Contrast: PlusTherapeuticsInc . vs. Stryker
Contrasting Sito Mobile  and Invictus Financial
Contrasting Sito Mobile and Invictus Financial
Pinnacle Financial Partners  Rating Reiterated by Stephens
Pinnacle Financial Partners Rating Reiterated by Stephens
Goldman Sachs Group Trims New Relic  Target Price to $52.00
Goldman Sachs Group Trims New Relic Target Price to $52.00
L3Harris  PT Raised to $250.00 at Jefferies Financial Group
L3Harris PT Raised to $250.00 at Jefferies Financial Group


 
© 2006-2019 Zolmax.